Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAUR | Q03405 | 3/20 | 0.56 |
| ▸ | DHODH | Q02127 | 4/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | CTRC | Q99895 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14907387 | 0.86 | PLAUR (0.52) | PLAURDHODHCYP2C9CYP3A4CYP2C8 | |
| SCHEMBL13957864 | 0.76 | HSD17B10 (0.69) | DHODHCYP2C9PDE10AMAPTKDM4E | |
| SCHEMBL1898779 | 0.75 | KDM4E (0.76) | DHODHCYP3A4PDE10AKDM4ELMNA | |
| SCHEMBL13957862 | 0.75 | LMNA (0.57) | DHODHCYP2C9CYP3A4PDE10AMAPT | |
| SCHEMBL14907393 | 0.74 | CYP3A4 (0.45) | PLAURDHODHCYP2C9CYP3A4CYP2C8 | |
| Hydrochloric Acid SCHEMBL10757465 | 0.74 | KDM4E (0.73) | DHODHCYP3A4PDE10AKDM4ELMNA | |
| SCHEMBL13458970 | 0.73 | MAPK1 (0.55) | CTRCPPARAMAPTKDM4ELMNA | |
| SCHEMBL8619739 | 0.73 | PPARA (0.69) | DHODHPDE10APPARAMAPTKDM4E | |
| SCHEMBL28640320 | 0.73 | SLC6A3 (0.64) | CTRCSMN1; SMN2CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL13458894 | 0.72 | CTRC (0.54) | CTRCMAPTKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819662-B1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2019-04-10 | — | — | EP | disclosed |
| US-9552457-B2 | Reprogramming effector protein interactions to correct epigenetic defects in cancer | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-01-24 | — | — | US | disclosed |
| US-9552457-B2 | Reprogramming effector protein interactions to correct epigenetic defects in cancer | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-01-24 | — | — | US | disclosed |
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-06-04 | — | — | US | disclosed |
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-06-04 | — | — | US | disclosed |
| WO-2013127011-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013059944-A1 | EPIGENETIC REGULATORS AND USES THEREOF | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | CBX2, BPTF, CBX4 | PLAUR 3439/4885DHODH 2520/4885CYP2C9 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.